Zinc deficiency alters responsiveness to antidepressant drugs in mice
Tóm tắt
There is some evidence coming from preclinical and clinical studies suggesting a relationship between dietary zinc intake and depressive symptoms. The aim of the study was to determine whether zinc deficiency alters the response to antidepressants with a different mechanism of action. We examine also whether these changes are related to activity of the hypothalamic-pituitary-adrenal HPA axis. Male CD-1 mice were assigned to groups according to diet and antidepressant administration. To evaluate animal behavior, the immobility time in the forced swim test (FST) and locomotor activity were measured. To determine serum zinc levels the flame atomic absorption spectroscopy (FAAS) was used. The serum corticosterone was determined by radioimmunoassay (RIA). Antidepressants administered to zinc-deprived mice induced an altered response in the FST when compared to animals fed with an adequate diet. There were no changes in locomotor activity. Animals subjected to a zinc-deficient diet showed a significant reduction in serum zinc levels, which was normalized by antidepressant treatment. An increase in serum corticosterone concentrations in mice fed with a zinc-deficient diet and treated with antidepressants was observed, so it can be concluded that reduced levels of zinc contribute hyperactivation of the HPA axis. The results of this study suggest that a diet with a reduced zinc level alters antidepressant action, which is associated with a reduction in the serum zinc level and rise in the corticosterone level. The results of this study may indicate the involvement of zinc deficiency in the pathogenesis of depression.
Tài liệu tham khảo
Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ: Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry, 2010, 67, 139–145.
Berlim MT, Turecki G: What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol, 2007, 17, 696–707.
Brown KH, Wuehler SE, Peerson JM: The importance of zinc in human nutrition and estimation of the global prevalence of zinc deficiency. Food Nutr Bull, 2001, 22, 113–125.
Castagné V, Moser P, Roux S, Porsolt RD: Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci, 2011, Chapter 8: Unit 8.10 A.
Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME: Zinc and human health. An update. Arch Toxicol, 2012, 86, 521–534.
Cieślik K, Klenk-Majewska B, Danilczuk Z, Wróbel A, Łupina T, Ossowska G: Influence of zinc suplementation on imipramine effect in a chronic unpredictable stress (CUS) model in rats. Pharmacol Rep, 2007, 59, 46–52.
Cieślik K, Sowa-Kućma M, Ossowska G, Legutko B, Wolak M, Opoka W, Nowak G: Chronic unpredictable stress-induced reduction in the hippocampal brainderived neurotrophic factor (BDNF) gene expression is antagonized by zinc treatment. Pharmacol Rep, 2011, 63, 537–543.
Cousins RJ, Dunn MA, Leinart AS, Yedinak KC, DiSilvestro RA: Coordinate regulation of zinc metabolism and metallothionein gene expression in rats. Am J Physiol, 1986, 251, 688–694.
Covvey JR, Crawford AN, Lowe DK: Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother, 2012, 46, 117–123.
Cunha MP, Machado DG, Bettio LEB, Capra JC, Rodrigues ALS: Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry, 32, 2008, 1913–1920.
Dhir A, Kulkarni SK: Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol, 2007, 568, 177–185.
Dhir A, Kulkarni SK: Nitric oxide and major depression. Nitric Oxide, 2011, 24, 125–31.
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA et al.: A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry, 2010, 67, 793–802.
Duman RS, Li N, Liu RJ, Duric V, Aghajanian G: Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology, 2012, 62, 35–41.
Fava M: Diagnosis and definition of treatment-resistant depression. Biol Psychiatry, 2003, 53, 649–659.
Fava M, Davidson KG: Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am, 1996, 19, 179–200.
Hamon M, Bourgoin S: Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects? Eur Neuropsychopharmacol, 2006, 16, 625–632.
Hashimoto K: Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev, 2009, 61, 105–123.
Hashimoto K: The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol Biol Psychiatry, 2010, 35, 1558–1568.
Kroczka B, Branski P, Palucha A, Pilc A, Nowak G: Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull, 2001, 55, 297–300.
Kroczka B, Ziêba A, Dudek D, Pilc A, Nowak G: Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol J Pharmacol, 2000, 52, 403–406.
Levenson CW: Zinc: The new antidepressant? Nutr Rev 2006, 64, 39–42.
Maes M, De Vos N, Demedts P, Wauters A, Neels H: Lower serum zinc in major depression in relation to changes in serum acute phase proteins. J Affect Disord, 1999, 56, 189–194.
Maes M, D’Haese PC, Scharpé S, D’ Hondt P, Cosyns P, De Broe ME: Hypozincemia in depression. J Affect Disord 1994, 31, 135–140.
Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord, 1995, 34, 301–309.
Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyder R: Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry, 1997, 42, 349–358.
Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS: Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol, 2010, 13, 71–82.
Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW: Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs, 2012, 26, 189–204.
McLoughlin IJ, Hodge JS: Zinc in depressive disorder. Acta Psychiatr Scand, 1990, 82, 451–453.
Młyniec K, Davies CL, Budziszewska B, Opoka W, Reczyński W, Sowa-Kućma M, Doboszewska U et al.: Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test. Pharmacol Rep, 2012, 64, 567–575.
Młyniec K, Nowak G: Zinc deficiency induces depression-like behavior in the tail suspension test in mice. Pharmacol Rep, 2012, 64, 249–255.
Musazzi M, Racagni G, Popoli M: Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs. Neurochem Int, 2011, 59, 138–149.
Nowak G, Schlegel-Zawadzka M: Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc. Biol Trace Elem Res, 1999, 67, 85–92.
Nowak G, Siwek M, Dudek D, Zięba A, Pilc A: Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol, 2003, 55, 1143–1147.
Nowak G, Szewczyk B, Pilc A: Zinc and depression. An update. Pharmacol Rep, 2005, 57, 713–718.
Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, Sadlik K, Piekoszewski W: Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbec-tomy model in rats. Brain Res Bull, 2003, 61, 159–164.
Nowak G, Zieba A, Dudek D, Krosniak M, Szymaczek M, Schlegel-Zawadzka M: Serum trace elements in animals models and human depression. Part I. Zinc. Hum Psychopharmacol Clin Exp, 1999, 14, 83–86.
Paoletti P, Ascher P, Neyton J: High-affinity zinc inhibition of NMDA NR1-NR2 receptors. J Neurosci, 1997, 17, 5711–5725.
Pennix BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S, Ferrucci L et al.: Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry, 2003, 54, 566–572.
Porsolt RD, Bertin A, Jalfre M: Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther, 1977, 229, 327–336.
Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW: An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol, 2008, 28, 631–637.
Rosa AO, Lin J, Calixto JB, Santos ARS, Rodrigues ALS: Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res, 2003, 144, 87–93.
Rush AJ, Thase ME, Dube S: Research issues in the study of difficult-to-treat depression. Biol Psychiatry, 2003, 53, 743–753.
Sanacora G, Treccani G, Popoli M: Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology, 2012, 62, 63–77.
Siwek M, Dudek D, Paul IA, Sowa-Kucma M, Zieba A, Popik P, Pilc A, Nowak G: Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord, 2009, 118, 187–195.
Siwek M, Dudek D, Schlegel-Zawadzka M, Morawska A, Piekoszewski W, Opoka W, Zieba A et al.: Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J Affect Disord, 2010, 126, 447–452.
Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol, 1999, 375, 31–40.
Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R: Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopschiatry, 1996, 29, 23–26.
Skolnick P, Popik P, Trullas R: Glutamate-based antide-pressants: 20 years on. Trends Pharmacol Sci, 2009, 30, 563–569.
Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K: Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci, 1995, 762, 474–476.
Souery D, Amsterdam J, De Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G et al.: Treatmentresistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol, 1999, 9, 83–91.
Sowa-Kućma M, Legutko B, Szewczyk B, Novak K, Znojek P, Poleszak E, Papp M et al.: Antidepressant-like activity of zinc: further behavioural and molecular evidence. J Neural Transm, 2008, 115, 1621–1628.
Soygur H, Palaoglu O, Akarsu ES, Cankurtaran ES, Ozalp E, Turhan L, Ayhan IH: Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31, 1242–1247.
Szewczyk B, Palucha-Poniewiera A, Poleszak E, Pilc A, Nowak G: Investigational NMDA receptor modulators for depression. Expert Opinion on Investig Drugs, 2012, 21, 91–102.
Szewczyk B, Poleszak E, Sowa-Kućma M, Siwek M, Dudek D, Ryszewska-Pokraśniewicz B, Radziwoń-Zaleska M et al.: Antidepressant activity of zinc and magnesium in view of the current hypotheses of antide-pressant action. Pharmacol Rep, 2008, 60, 588–599.
Szewczyk B, Poleszak E, Wlaź P, Wróbel A, Blicharska E, Cichy A, Dybala M et al.: The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Progr Neuropsychopharmacol Biol Psychiatry, 2009, 33, 323–329.
Takeda A, Tamano H: Zinc signaling through glucocorticoid and glutamate signaling in stressful circumstances. J Neurosci Res, 2010, 88, 3002–3010.
Takeda A, Tamano H, Itoh H, Oku N: Attenuation of abnormal glutamate release in zinc deficiency by zinc and Yokukansan. Neurochem Int, 2008, 53, 230–235.
Takeda A, Tamano H, Kan F, Itoh H, Oku N: Anxietylike behavior of young rats after 2-week zinc deprivation. Behav Brain Res, 2007, 177, 1–6.
Takeda A, Tamano H, Ogawa T, Takada S, Ando M, Oku N, Watanabe M: Significance of serum glucocorticoid and chelatable zinc in depression and cognition in zinc deficiency. Behav Brain Res, 2012, 226, 259–254.
Takeda A, Tamano H, Tochigi M, Oku N: Zinc homeo-stasis in the hippocampus of zinc-deficient young adult rats. Neurochem Int, 2005, 46, 221–225.
Takeda A, Yamada K, Tamano H, Fuke S, Kawamura M, Oku N: Hippocampal calcium dyshomeostasis and long-term potentiation in 2-week zinc deficiency. Neurochem Int, 2008, 241–246.
Tamano H, Kan F, Kawamura M, Oku N, Takeda A: Behavior in the forced swim test and neurochemical changes in the hippocampus in young rats after 2-week zinc deprivation. Neurochem Int, 2009, 55, 536–541.
Tassabehji NM, Corniola RS, Alshingiti A, Levenson CW: Zinc deficiency induces depression-like symptoms in adult rats. Physiol Behav, 2008, 95, 365–369.
Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol, 1990, 185, 1–10.
Van Den Eede F, Claes SJ: Mechanisms of depression: role of the HPA axis. Drug Discov Today, 2004, 1, 413–418.
Vetulani J, Nalepa I: Antidepressants: past, present and future. Eur J Pharmacol, 2000, 405, 351–363.
Watanabe M, Tamano H, Kikuchi T, Takeda A: Susceptibility to stress in young rats after 2-week zinc deprivation. Neurochem Int, 2010, 56, 410–416.
Whittle N, Lubec G, Singewald N: Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice. Amino Acids, 2009, 36, 147–158.
Wójcik J, Dudek D, Schlegel-Zawadzka M, Grabowska M, Marcinek A, Florek E, Piekoszewski W et al.: Antepartum/postpartum depressive symptoms and serum zinc and magnesium levels. Pharmacol Rep, 2006, 58, 571–576.
Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry, 2004, 161, 171–174.
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006, 63, 856–864.